Literature DB >> 31525448

Alteration of antibiotic regimen as an additional control measure in suspected multi-drug-resistant Enterobacter cloacae outbreak in a neonatal intensive care unit.

V Eichel1, C Papan2, S Boutin3, J Pöschl4, K Heeg3, D Nurjadi3.   

Abstract

BACKGROUND: Increased occurrence of a particular species of Gram-negative bacteria (GNB), especially when multi-drug-resistant (MDR), in routine screening surveillance in neonatal intensive care units (NICUs) can be evoked by selection pressure. AIM: To evaluate adaptation of the empiric antibiotic regimen for its usefulness as a control measure in suspected outbreaks in the NICU.
METHODS: In a retrospective outbreak analysis, cases between 1st December 2017 and 31st March 2018 were identified through microbiology and hygiene surveillance records. Furthermore, risk factors for MDR-GNB colonization were collected. Whole-genome sequencing (WGS) was performed on all isolates. Control measure documentations and interviews were employed to define interventions. As well as infection control measures, administration of third-generation cephalosporins was avoided and replaced whenever clinically acceptable as part of the intervention bundle.
FINDINGS: In total, nine patients were found to have rectal colonization with third-generation cephalosporin-resistant Enterobacter cloacae in routine screening surveillance in the pre-intervention period. After implementation of an infection control bundle, the incidence declined rapidly. WGS analysis revealed that two MDR E. cloacae were transmitted, and the majority were new cases. The incidence density of MDR-GNB colonization was 7.94/1000 patient-days (PD) before the intervention and 1.68/1000 PD during the altered antibiotic regimen. No infections with MDR-GNB occurred during the study.
CONCLUSIONS: Altering the antibiotic regimen with regard to selection pressure may be considered as part of an intervention bundle to rapidly control the emergence of MDR-GNB in suspected outbreak situations in the NICU.
Copyright © 2019 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Empiric antibiotic treatment; Infection control; MDR; NICU; Outbreak management

Mesh:

Substances:

Year:  2019        PMID: 31525448     DOI: 10.1016/j.jhin.2019.09.007

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  4 in total

1.  Enterobacter cloacae colonisation and infection in a neonatal intensive care unit: retrospective investigation of preventive measures implemented after a multiclonal outbreak.

Authors:  Alexandrine Ferry; Frank Plaisant; Christophe Ginevra; Yann Dumont; Jacqueline Grando; Olivier Claris; François Vandenesch; Marine Butin
Journal:  BMC Infect Dis       Date:  2020-09-17       Impact factor: 3.090

2.  Genomic Investigation and Successful Containment of an Intermittent Common Source Outbreak of OXA-48-Producing Enterobacter cloacae Related to Hospital Shower Drains.

Authors:  Dennis Nurjadi; Martin Scherrer; Uwe Frank; Nico T Mutters; Alexandra Heininger; Isabel Späth; Vanessa M Eichel; Jonas Jabs; Katja Probst; Carsten Müller-Tidow; Juliane Brandt; Klaus Heeg; Sébastien Boutin
Journal:  Microbiol Spectr       Date:  2021-11-24

3.  Contaminated Incubators: Source of a Multispecies Enterobacter Outbreak of Neonatal Sepsis.

Authors:  Enrique Hernandez-Alonso; Nadège Bourgeois-Nicolaos; Margaux Lepainteur; Véronique Derouin; Simon Barreault; Adam Waalkes; Luis A Augusto; Stuti Gera; Orane Gleizes; Pierre Tissieres; Stephen J Salipante; Daniele de Luca; Florence Doucet-Populaire
Journal:  Microbiol Spectr       Date:  2022-06-15

4.  Combined antibiotic stewardship and infection control measures to contain the spread of linezolid-resistant Staphylococcus epidermidis in an intensive care unit.

Authors:  Cihan Papan; Matthias Schröder; Mathias Hoffmann; Heike Knoll; Katharina Last; Frederic Albrecht; Jürgen Geisel; Tobias Fink; Barbara C Gärtner; Alexander Mellmann; Thomas Volk; Fabian K Berger; Sören L Becker
Journal:  Antimicrob Resist Infect Control       Date:  2021-06-30       Impact factor: 4.887

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.